G1 Therapeutics Lowers 2023 Net Revenue Guidance Due To Ongoing Shortage Of Platinum-Based Chemotherapy; Expects $44M-$47M (Prior View $50M-$60M) In COSELA Net Revenue
Portfolio Pulse from Benzinga Newsdesk
G1 Therapeutics has lowered its 2023 net revenue guidance due to an ongoing shortage of platinum-based chemotherapy. The company now expects $44M-$47M in COSELA net revenue, down from the previous estimate of $50M-$60M.
November 01, 2023 | 10:43 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
G1 Therapeutics has lowered its 2023 net revenue guidance due to a shortage of platinum-based chemotherapy, which may negatively impact its stock price in the short term.
G1 Therapeutics' lowered revenue guidance is a direct result of an ongoing shortage of platinum-based chemotherapy. This shortage impacts the company's ability to generate revenue from its COSELA product, leading to a decrease in expected net revenue. This news is likely to negatively impact investor sentiment and could lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100